{"id":"NCT00484289","sponsor":"Bristol-Myers Squibb","briefTitle":"A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis","officialTitle":"A Phase III, Multi-center, Open-label, Uncontrolled, Long-term Study to Evaluate the Safety of Abatacept (BMS-188667) in Japanese Subjects With Rheumatoid Arthritis Having Completed Clinical Studies IM101-071, IM101-034, and Also Special DMARD Failures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2010-12","completion":"2010-12","firstPosted":"2007-06-08","resultsPosted":"2012-08-09","lastUpdate":"2013-06-24"},"enrollment":217,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Abatacept","otherNames":["Orencia®","BMS-188667"]}],"arms":[{"label":"Arm 1: Participants from Phase I study (IM101-034)","type":"EXPERIMENTAL"},{"label":"Arm 2: Participants from Phase II study (IM101-071)","type":"EXPERIMENTAL"},{"label":"Arm 3: New Participants with Methotrexate (MTX) Intolerance","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to demonstrate the safety of chronic use of abatacept in Japanese Subjects with Rheumatoid Arthritis (RA) having completed clinical studies IM101-071, IM101-034, and also Disease Modifying Anti-Rheumatic Drugs (DMARDs) failures with MTX intolerance.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to AEs","timeFrame":"From initiation of the study drug (31 Mar 2008) to data cutoff (27 Dec 2010). The overall mean duration of exposure to the study drug was approximately 3 years (34.3 ± 10.7 months).","effectByArm":[{"arm":"Participants From Phase I Study (IM101-034); Abatacept 10mg/kg","deltaMin":4,"sd":null},{"arm":"Participants From Phase II Study(IM101-071); Abatacept 10mg/kg","deltaMin":50,"sd":null},{"arm":"New Participants With MTX Intolerance; Abatacept 10 mg/kg","deltaMin":14,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":39,"countries":["Japan"]},"refs":{"pmids":["24754273"],"seeAlso":["http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":13},"commonTop":["Nasopharyngitis","Stomatitis","Blood pressure increased","Lymphocyte count decreased","White blood cell count increased"]}}